Home > Executive Order

AI Summary: This policy document is an amendment to an existing Executive Order (EO) from February 1, 2025, which addresses the synthetic opioid supply chain in China. The amendment specifically modifies subsection (g) of section 2 of the original EO, focusing on duty-free de minimis treatment for certain covered articles. Under the new language, the de minimis treatment (which allows for reduced or no tariffs on small shipments) will remain available for eligible articles until the Secretary of Commerce notifies the President that adequate systems are in place to process and collect tariff revenue for these articles. The document also includes standard boilerplate language about the order's implementation, which clarifies that it does not impair existing executive authorities, must be implemented consistent with applicable law, and does not create enforceable legal rights for any party.